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Problems in Extrapolating Toxicity
Data for Laboratory Animals to Man
by R. L. Dixon*
Some ofthe problems in extrapolating laboratory animal toxicity data to man are con-
sidered. The quantitative predictiveness of preclinical studies of anticancer drugs using
dogs and monkeys for man has also been examined. The relationship between the max-
imum tolerated dose (MTD) in the dog, monkey, and the more sensitive of the two species
and clinical observations are discussed. The effectiveness of using doses expressed on the
basis ofbody weight (mg/kg) and body surface area (mg/M2) are compared. A method is in-
troduced to assess the "statistical risk" associated with the extrapolation of the initial
clinical (phase I) dose from experimental animal data. The best clinical prediction is ob-
tained when one uses the experimental MTD expressed in mg/kg for the more sensitive of
the large animal species (dogs or monkeys). The clinical introduction of a new anticancer
agent at a dose 1/10 the MTD in the more sensitive species carries a statistical risk ofabout
3%; that is, the initial doses ofabout 3 ofevery 100 new drugs introduced into the clinic will
produce some toxic effects in man. These same data have been extended theoretically to
the total population and toxic chemicals in general. Reliable extrapolation from laboratory
test models to man requires a much more complete understanding of structure-activity
relationships, pharmacokinetic factors, and mechanisms of toxicity.
There appears to be worldwide agreement con-
cerning the fact that extrapolating laboratory
animal toxicity data to man remains a major
unresolved problem intoxicology. Predictiveness of
laboratory models must include both qualitative
(clinical signs, chemical, hematologic, and
pathologic lesions) and quantitative (dose or ex-
posure level) aspects. Sidorenko and Pinigin (1)
and other Soviet scientists (2) have described the
multifaceted questions which remain with regard
to predicting biological effects and identifying
harmful environmental substances. A complete un-
derstanding ofthe toxicodynamic parameters must
be achieved to allow reliable predictiveness. The
lack ofunderstanding in this area makes the build-
ing of mathematical models for extrapolation
unreliable at the present time.
The ever-present need to establish reasonable
and safe maximally permissible concentrations for
various environmental chemicals adds emphasis to
this task. Soviet and American toxicologists agree
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that greater efforts must be devoted to revealing
the relationship between the physicochemical prop-
erties of a substance and its biological effect
(structure-activity relationship, SAR), to studying
the effects of accumulation, potentiation and an-
tagonism, and to evaluating the state ofadaptation
of test animals.
Safety evaluation is the major goal oftoxicology
while the reliable estimate of human risk is the
greatest challenge. Weil (3) has offered the follow-
ing guidelines for experiments where the results are
to be used to predict the degree of safety of a
material for man.
1. Wherever practical or possible, one or more
species should be used that biologically handle the
material qualitatively and/or quantitatively as
similarly as possible to man. For this, metabolism,
absorption, excretion, storage, and other physio-
logical effects might be considered.
2. Where practical, several dose levels should be
used, on the principle that all types of toxicologic
and pharmacologic actions in man and animals are
dose-related. The only exception to this should be
the use of a single, maximum dosage level if the
material is relatively nontoxic; this level should be
February 1976 43a sufficiently large multiple of that which is at-
tainable by the maximum applicable hazard ex-
posure route, and should not be physiologically im-
practical.
3. Effects produced at higher dose levels are
useful for delineating mechanism of action, but for
any material and adverse effects, some dose level
exists for man or animal below which this adverse
effect will not appear. This biologically insignifi-
cant level can and should be set by use of a proper
safety factor and competent scientific judgment.
4. Statistical tests for significance are valid only
on the experimental units (e.g., either litters or in-
dividuals) that have been mathematically ran-
domized among the dosed and concurrent control
groups. It is to be understood that statistical sig-
nificance may be of little or no biological impor-
tance, and, conversely, that important biological
trends should be further examined even in the ab-
sence of statistical significance.
5. Effects obtained by one route of administra-
tion to test animals are not a priori applicable to
effects by another route of administration to man.
The routes chosen for administration to test
animals should, therefore, be the same as those to
which man will be exposed. Thus for example, food
additives for man should be tested by admixture of
the material in the diet of animals.
Weil properly emphasizes the importance of
phatmacokinetics, dose-response relationships,
toxic thresholds, statistical reasonableness, and
selection of the appropriate route of administra-
tion. Although these aspects should need no further
emphasis, it is apparent from the problems which
continually arise regarding safety assessments that
many toxicologists fail to fully appreciate these im-
portant points.
Our increased understanding of phar-
macokinetics, especially the role of enzymes which
either degrade or activate chemical substances, as
well as the recent significant advances in in vitro
and lower animal biological tests emphasized the
complexity of this overall problem.
There are three questions that must be con-
sidered regarding the interspecies comparison of a
toxic agent: What chemical is the toxic agent? How
much ofthe agent is present at sites ofaction? How
long is that agent present?
The question of identity of the agent must in-
clude studies of metabolic alterations of the com.
pound by each ofthe species considered. The ques-
tion of amount or concentration of agent is a func-
tion of not only the metabolism, but also of dis-
tribution and elimination rates as well as various
environmental and physiological factors. How long
the susceptible cells or receptors are exposed to the
toxic agent is a function of environmental ex-
posure, distribution and elimination by metabol-
ism, tissue uptake, and/or excretion. These are all
problems which involve the pharmacologic disposi-
tion or pharmacokinetics of the toxic agent.
If one is trying to extrapolate from a laboratory
experiment to man, it is also important to ask how
well the laboratory test situation reflects man and
his environment. There are obviously great
differences in the genetic make-up of the human
population. Every aspect of the handling and
elimination ofa chemical bythe body is potentially
involved in this human heterogeneity. It is also
necessary to realize the very selective nature of
most experimental test populations. Experimen-
talists tend to select vigorous, well fed, healthy
animals to extrapolate to a population which con-
tains subpopulations that have all varieties of ill-
ness, weakness, and disease. This problem has been
described by Rall as the "median mouse" to "me-
dian man" consideration. That is, in a very
homogeneous population under strict environmen-
tal control, what are the differences in response
between a very small mammal with its own
peculiar set ofmetabolic processes and a relatively
large mammal, man, with his own peculiar set of
physiological, biochemical, and pharmacological
processes? It must be kept in mind that the final
organism one is attempting to protect is not "me-
dian man" but every single individual in a very
large and diverse population.
It is readily apparent that there are differences
among experimental animals, between experimen-
tal animals and man, and among different in-
dividuals of the same species, but there are also
similarities. Knowledge of these similarities and a
proper accounting for differences will eventually
lead to rational pharmacokinetic models. Such
models will allow an investigator to rapidly syn-
thesize many observations and quantitatively
describe the time-course of drug concentrations at
various tissue receptors in various species.
Zharako and Dedrick (4) have attempted to use
existing anatomical, biochemical, and physiologi-
cal information to construct more meaningful
model systems for interspecies comparisons. With
respect to the pharmacokinetic aspects of these
types of models, the compartments and rate con-
stants have a physiological basis in addition to a
drug data basis. These model systems are being
developed in an effort to "scale up" data from one
species to another. These investigators studying the
Environmental Health Perspectives 44pharmacological disposition of methotrexate in
mice have been able to predict plasma and several
tissue drug concentrations in rats, dogs, monkeys,
and humans when the mouse model paranmeters
were adjusted appropriately on the basis of known
or measured physiological and pharmacological
differences among the species.
Each compartment of their model is identified
with an anatomic rather than functional space
which permits incorporation of concepts from
physiology, membrane transport, and enzyme
kinetics at the local site. Furthermore, attempts
can be made to correlate metabolism, transport,
and cell response in vivo with measurements made
in vitro.
However, one must be continually aware that
the mathematically correct solution may not al-
ways represent the biological solution. Kinetic
models like whole animal tests usually apply only
to the average or median animal in the population.
Although progress has been made, the complicated
nature of interspecies comparison and biological
test procedures have largely ruled out any attempt
to offer some universal mathematical extrapola-
tion factor which would allow interspecies com-
parisons (including man) for all environmental
substances; neither is there such a factor to equate
in vitro test results to whole animal studies.
Most ofthe evaluations regarding the predictive-
ness of laboratory animal toxicology for man have
focused on therapeutic agents in the United states.
The publications of Schein (5) and Freireich (6)
and their co-workers regarding antineoplastic
agents are especially important in this area. These
studies were supported by complete preclinical tox-
icology and carefully conducted clinical studies.
The problems with regard to environmental agents
are even more difficult. Environmental toxicology
is concerned primarily with the biological effects of
chemicals that are encountered by man either inci-
dentally because they are in the atmosphere, by
contact during occupational or recreational ac-
tivities, or by ingestion with water or food. In con-
trast to therapeutic agents, no one is entirely free of
exposure to a variety of chemicals capable of pro-
ducing undesirable effects on biologic tissues. The
real and potential hazards of environmental
chemicals are difficult to define, exposure levels are
hard to quantitate, and acute toxicity is much less
of a concern than are long-term risks such as.car-
cinogenesis and mutagenesis.
The usefulness ofanimal studies in predicting ir-
reversible toxicity such as mutagenesis and car-
cinogenesis and the extrapolation of exposure
levels to estimate human risk are especially
difficult problems and are receiving deserved atten-
tion. These areas will be discussed by others at this
symposium.
The problems involved in extrapolating to
humans results ofnewly developed test systems ap-
plied in vitro and lower animals, although not dis-
cussed here, is an area needing additional study
and perhaps should be considered for future col-
laborative efforts.
This paper will be concerned with the prediction
of toxicity in man by using laboratory models,
especially dogs and monkeys. Initially, I would like
to describe some of our work with regard to the
quantitative relationship of drug-related toxicity,
and more specifically with the extrapolation from
preclinical studies of the starting dose for the in-
itial (phase I) clinical trial in man (7). The data to
be described here are the result of applied tox-
icologic studies performed in support ofthe clinical
introduction of new chemicals for the treatment of
cancer. These considerations are somewhat super-
ficial and restricted due to the fact that many ques-
tions regarding the chemical mechanisms of action,
and the adsorption, distribution, excretion, and
metabolism ofthese drugs are unanswered. We ex-
amined the quantitative predictiveness of dog and
monkey toxicologic studies for the human patient.
Our analyses attempt to answer two questions: (1)
What is the quantitative relationship of drug doses
based on kilogram of body weight (mg/kg) and
square meter ofbodysurface (mg/M2) for prediction
of toxic doses in man? (2) What is the "statistical
risk" oftoxicity associated with various extrapola-
tions of the initial clinical dose from dog and/or
monkey toxicity studies? The application of these
data to environmental chemicals and the selection
ofreasonable safety factors will also be considered.
The primary source ofdata used are the publica-
tions by Schein et al. (5) and Freireich et al. (6).
These papers evaluate the quantitative and
qualitative predictiveness of experimental animals
for man, and include tabulated toxicity data for
many antineoplastic agents. Data are summarized
asthe maximum tolerated dose (MTD) for each an-
ticancer agent for a variety of treatment regimens
based on doses expressed in terms of mg/kg and
mg/M2. All of the large experimental animal data
were obtained from studies performed for the
Laboratory of Toxicology on contracts with
research laboratories. Clinical data were collected
by the National Cancer Institute and its cooperat-
ing clinical groups. Three important simplifying
restrictions were applied to the handling of the
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multiple daily doses (five or more) in both experi-
mental animals and man were included; (2)
evaluation ofthe data was based on total dose ad-
ministered; and (3) the individual authors' defini-
tions of the maximum tolerated dose were ac-
cepted.
For comparison of dose bases, MTDs were plot-
ted as logarithms, least-squares regression analysis
performed, and comparisons made either
mathematically or visually.
To estimate the statistical risk associated with
the extrapolation of initial clinical doses from dog
and/or monkey toxicity data, ratios of the clinical
and experimental (clinical/experimental) MTDs
were determined and ranked from the lowest to the
highest ratio. A cumulative percent figure was
calculated for each ranked ratio by dividing and
ranking by one more than the total number of
drugs being studied (n i- 1). When the clini-
cal/experimental MTD ratios are expressed as
logarithms (or numerically on log-probit paper),
the population of ratios (drugs) is normally dis--
tributed. If one draws a random sample from a
population which is normally distributed, the or-
dered observations would be expected to approxi-
mate a linear function of representative values.
This procedure is based on a statistical method
known as the empirical cumulative distribution
function. Stated simply, the approach is essentially
equivalent to the log-probit transformations used
routinely in pharmacology to determine drug levels
associated with median effects. Forthe presentpur-
poses, it is sufficient to state that this method pro-
vides a convenient way of describing and compar-
ing the distribution ofvalues and requires only the
assumption of normal distribution of the
logarithms of the MTD ratios which can be
demonstrated.
This method allows for the determination or
estimation ofthe statistical risk associated with the
clinical introduction of any new drug when the
clinical/experimental MTD ratios are associated
with a cumulative fraction of the total sample of
ratios for similar drugs. For example, if the mean
ratio of clinical to animal tolerated dose was 1
(perfect predictability) then, depending on varia-
tion, one would expect half of the drugs to be less
toxic to humans and halfto be more toxic ifthe ex-
perimental MTD was administered initially to,
man. This, of course, is never done. A point of par-
ticular interest is the percent probability of exceed-
ing a certain clinical/experimental MTD ratio, e.g.,
0.1, for the more sensitive experimental species and
man. This would indicate statistically the percent
of drugs introduced into the clinic which are more
than 10 times as toxic to man than to the experi-
mental species. New anticancer agents are most
often introduced into the clinic as 1/10 the mg/kg
MTD in the most sensitive experimental species
(dog or monkey).
Pinkel (8) studied the toxicity of antitumor
agents and found interspecies correlation to be very
good, provided doses were expressed in terms of
milligrams of drug per square meter of body sur-
face area (mg/M2) rather than milligrams per
kilogram body weight (mg/kg). Freireich et al. (6),
studying a variety of antitumor agents and using
several animal species, have extended the work of
Pinkel. Our study further analyzes the data ofboth
Freireich et al. (6) and Schein et al. (5). A tabula-
tion was made of the maximum tolerated doses
(MTDs) for monkey, dog, and man for more than
40 antitumor drugs. The predictiveness of dog and
monkey MTDs for man has been examined for
doses based on both mg/kg and mg/Mi2. Since it is
the practice to use the MTD ofthe more sensitive of
the two species as the basis for extrapolation of
phase I clinical doses, a similar analysis was car-
ried out using the more sensitive species as the
basis of the independent variable.
To further investigate the relationship between
doses expressed as mg/kg and mg/M2, data from
Schein et al. (5) were added to those for the drugs
previously studied by Freireich. Figure 1 presents
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FIGURE 1. Relationship between human and dog MTD based
on mg/kg doses.
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46these data for the dog and compares the MTDs for
dog and man based on mg/kg. This representative
plot indicates the scatter ofthe actual data points.
Data are expressed as logarithms because of the
range of doses encountered. Ifthe relationships be-
tween the MTDs in the two species were perfect,
then the data would obviously fall along the
diagonal line.
Figure 2 presents the calculated best-fitting
straight lines for MTDs for the dog, monkey and
most sensitive ofthetwo speciestested compared to
man. Data based on mg/kg and mg/M2 are repre-
sented. It is obvious that there is little difference
between the curves.
Table 1 summarizes the important points from
this type of analysis. The mean MTD ratios (clini-
cal/experimental) were calculated statistically
from the log distributions. The expected median of
the ratios of clinical/experimental MTD was
derived by regressional analyses. For mg/kg doses,
the average calculated clinical MTD is 0.9 times
the dose observed in dogs. That is, the clinical
MTD is 10% less than the predicted dose. Clinical
mg/kg MTDs are, on the average, halfthe dose pre-
dicted by monkey studies and have a clini-
cal/experimental MTDratio of0.5. Ifthe most sen-
sitive animal species is used and the dose expressed
onmg/kg basis, theprediction is nearlyperfect. The
clinical/experimental MTD ratio is 1.0. The more
sensitive species provides a safety margin over
using either dog or monkey data alone.
Using mg/M2 as the basis for the MTD does little
to improve the quantitative predictiveness (Table
1). The calculated clinical experimental MTD ratio
for dogs and monkeys is 1.7 and 1.6, respectively.
Therefore, the clinical dose associated with
minimaltoxicity is morethan 50% greaterthan the
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FIGURE 2. Relationship between human and experimental
MTD.
MTD in the experimental species. When the most
sensitive species is considered on a mg/M2basis, the
ratio ofthe clinical MTD to animal MTD is 2.2 in-
dicating that the clinical dose is more than twice
that predicted by large animal toxicology.
Therefore, although the mg/M2 extrapolation ap-
pears useful with smaller laboratory animals, the
conversion adds little to the extrapolation of dog
and monkey data to man.
The major effort of our recent data evaluations
has been directed to a consideration ofthe correla-
tion between experimental animal and clinical ob-
servations with respect to MTDs and the subse-
quent extrapolation to the clinical situation. Clini-
cal/experimental MTD ratios were ranked and
graphed as previously described. The individual
ratios of clinical/animal MTDs were considered to
be members of a normalized cumulative distribu-
tion and plotted using log-probit transformations.
With regression analysis, one can then associate
any dose ratio with a cumulative fraction of the
sample of ratios. Perfect prediction would be a
clinical/experimental MTD ratio of 1.0 correspond-
ing with the 0.5 (50% ) level ofthe cumulative dis-
tribution. The cumulative fractions may be con-
sidered numerically equivalent to the probability
that a given dose extrapolation will exceed the
clinical MTD, and thus provide an estimate ofthe
clinical risk for an untried clinical drug candidate
based on animal data and patterns ofrelationships
of similar drugs. As in the previous analyses, com-
parisons were made among dog, monkey, and the
more sensitive of these experimental species as
sources of the denominator of the MTD ratio and
between mg/kg and mg/M2 as means of dosage ex-
pression.
Figure 3 presents a representative plot. The
cumulative percent figure is indicated as the prob-
ability of exceeding human MTD on the ordi-
nate (probit units); the abscissa is the logarithm of
the clinical/experimental MTD ratio. This figure
Table 1. Comparison of observed experimental and clini-
cal maximum tolerated doses.
Basis of Experimental Mean MTD ratio,
comparison animal clinical/
experimental
mg/kg Dog 0.9
Monkey 0.5
More sensitive 1.0
mg/M2 Dog 1.7
Monkey 1.6
More sensitive 2.2
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presents data for monkeys, and the doses are ex-
pressed as mg/kg. The normal distribution of the
data is apparent.
Figure 4 is the calculated best-fitting straight
lines for dog, monkey, and more sensitive species
when compared to man. Data for doses based on
mg/kg and mg/M2 are included.
Table 2 presents tabulated figures on special in-
terest. The probability of exceeding a clini-
cal/experimental dose ratio of 0.1 (1/10) is indi-
cated. This would indicate that man is more than
10 times as sensitive as the experimental animal
and estimates the safety factor achieved when the
initial clinical dose is calculated as one tenth the
MTD in mg/kg for the most sensitive species. A
clinical dose one-tenth the dog mg/kg MTD carries
a 4 percent risk of exceeding the clinical MTD.
Statistically, 4 of 100 drugs will be introduced at a
dose greater than the human MTD. The corres-
ponding risk based on monkey data is 9%, and for
the more sensitive species, 3%.
More recently, it has been suggested that the in-
itial clinical dose be calculated as one third the ex-
perimental MTD in mg/M2 for the most sensitive
species. Analysis indicates equivalent risks for dogs
and monkeys are about 10% in each case; when the
most sensitive species is used, the risk is reduced to
approximately 6%. This risk is about twice that of
using one tenth the MTD dose expressed as mg/kg.
Table 2. Probability of exceeding human MTD with doses
based on MTD ratios.
Basis of Experimental Dose Probability of
comparison animal ratio exceeding human
MTD, %
mg/kg Dog 0.1 4.1
Monkey 0.1 8.7
More sensitive 0.1 2.9
mg/M2 Dog 0.1 1.3
0.33 10.0
Monkey 0.1 1.1
0.33 9.7
More sensitive 0.1 0.5
0.33 5.9
There is no question that some level ofrisk must
be accepted in the selection of the initial clinical
doses to insure that large numbers of seriously ill
patients do not receive ineffective drug levels. On
the other hand, the dose must not be so high that
the patient is subjected to unreasonable toxic
hazards.
The percent risk determined statistically in
these studies estimates the probable percentage of
new drugs that will exceed the MTD with the in-
itial dose during phase I clinical trials. Therefore,
two points are clear: clinicians conducting the
phase I trial must define an acceptable level of risk
for clinical toxicity, and it must be recognized that
statistically, with any level of risk selected, even-
tually a certain percentage of drugs will be in-
troduced into the clinic at doses which will produce
toxicity. The difficult question, of course, remains:
What level of risk is acceptable?
The acceptable risk for the general population
with regard to environmental chemicals is, of
course, very different from that just described for
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48Table 3. Probability of environmental chemicals exceeding human toxic threshold based on extrapolation from experi-
mental animal toxicology.
Percentage of experiment dose for varying degrees of safety
Experimental toxicological values 10% a 5% a 1% a 0.1% a 0.01% a 0.001% a
MTD
Dog (mg/kg) 17.13 9.46 3.05 0.84 0.29 0.114
Dog (mg/M2) 34.59 19.14 6.19 1.71 0.59 0.233
Monkey (mg/kg) 14.00 8.36 3.13 1.02 0.40 0.179
Monkey (mg/M2) 32.06 17.97 5.94 1.68 0.59 0.237
LD
Dog (mg/kg) 1.51 0.65 0.13 0.020 0.004 0.001
Dog (mg/M2) 2.76 1.16 0.22 0.034 0.007 0.002
Monkey (mg/kg) 0.78 0.35 0.07 0.013 0.003 0.001
Monkey (mg/M2) 5.48 2.76 0.75 0.168 0.049 0.017
aPercentage oftotal chemicals estimated to produce toxicity upon human exposure.
cancer patients. However, in this area also, some
degree of risk must be accepted; few chemicals are
without potential harmful effects.
The Environmental Biometry Branch at the
NIEHS has been helpful in extending these obser-
vations regarding clinical/experimental dose ratios
for antineoplastic drugs and the accompanying per-
cent risk of initial toxicity to the at large popula-
tion and toxic chemicals in general. Both doses
maximally toxic and lethal to experimental
animals are considered. There is one very impor-
tant caveat-an assumption is made that the
20-24 drugs studied represent a normally dis-
tributed population. This assumption appears
valid, but requires further study.
Table 3 summarizes these data. The percentages
of the experimental dose for varying degrees of
safety with regard to numbers of chemicals are in-
dicated. In this case, the percentage of the experi-
mental MTD associated with a predetermined level
of risk was determined. A good example is the
MTD dog (mg/kg) data because it represents the
NCI's clinical experience. Taking approximately
1/10 (9.46%) of the MTD dose in dogs indicates
that statistically 5% of the drugs (or chemicals)
will be introduced at a dose in excess ofthe human
MTD; 1/100 (0.84% ) of the experimental dose in
dogsreducestheriskto 1 drug (orchemical) in 1000.
One-thousandth (0.114% ) ofthe experimental dose
further reducestheriskofabout 1 in 100,000 chemi-
cals which will produce some toxicity in the human
population. This appears to be a low
estimate of the percentage of chemicals found to
have harmful human effects in today's world. A
single dose safety factor of 5,000 from the lowest
observed effect level has recently been proposed by
Weil. This factor probably provides adequate pro-
tection of the general population-from reversible
chronic toxicity. In fact, in many cases it is proba-
bly excessive. However, with regard to irreversible
chronic toxicity, the validity of this extrapolation
factor has yet to be determined; in these cases it
might be totally inadequate.
In summary, greater emphasis on achieving an
understanding of all aspects of interspecies varia-
tions is needed. Reliable extrapolation from
laboratory test models to man requires a more
complete understanding of structure-activity rela-
tionships, pharmacokinetic factors, and the
mechanisms of toxicity. Until that future time of
greater understanding, safety factors must be
determined for each substance considered based
not only on extrapolation from animal studies, but
supported by the informed judgment regarding as
many parameters as possible, and by selecting
those factors least likely to underestimate the risk
for man.
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